EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

CXCL16-driven CD4 + T cells orchestrate immunosurveillance against MHC-I-deficient hepatocellular tumors

Yunyi Zhou, Ping Chen, Zhixue Wang, Liming Gui, Zhengheng Zheng, Wei-Qiang Gao, Bin Ma

Journal for ImmunoTherapy of Cancer · 2026-05 · 14 (5) · e012347

DOI: 10.1136/jitc-2025-012347 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 12.05.2026. Verfasst von Yunyi Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory for Cancer System Regulation and Clinical Translation, Jiading District Central Hospital Affiliated Shanghai University of Me…. Hauptthemen laut MEDLINE: Liver Neoplasms, CD4-Positive T-Lymphocytes, Histocompatibility Antigens Class I, Chemokine CXCL16. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Science and Technology Commission of Shanghai Municipality, National 111 Project of China, Natural Science Foundation of Chongqing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Major histocompatibility complex class I (MHC)-I loss is a prevalent mechanism for immune evasion and resistance to immunotherapy. However, how MHC-I loss shapes the tumor microenvironment and influences immune cell interactions, ultimately affecting tumor growth, remains largely unknown.

Methods

We established B2m knockout (MHC-I-deficient) tumor cells using CRISPR/Cas9 and evaluated their growth in subcutaneous and orthotopic mouse models. Immune profiling was performed using flow cytometry and single-cell RNA sequencing. Antibody-mediated cell depletion was used to assess the functional contributions of specific immune subsets. Chemokine expression was analyzed by bulk RNA sequencing, quantitative PCR, ELISA and western blotting, and its functional relevance was determined using knockout or overexpression in tumor cells implanted in vivo. Signaling pathways were interrogated using pharmacological inhibition, RNA interference and western blotting.

Results

MHC-I loss promoted tumor growth in MC38, AKR, and LLC1 models, but unexpectedly suppressed Hepa1-6 and orthotopic MYC;Trp53 −/− hepatocarcinoma growth. This differential effect correlated with changes in immune infiltrates. CD4 + T cells, natural killer (NK) cells, and macrophages were required for suppression of MHC-I-deficient Hepa1-6 tumors. CD4 + T cells were essential for recruiting NK cells and monocytes/macrophages and for inducing their tumoricidal phenotypes, including iNOS (inducible nitric oxide synthase) expression in macrophages. The differential infiltration of CD4 + T cells was driven by opposite regulation of CXCL16 on B2m knockout: upregulation in Hepa1-6 cells and downregulation in other models. CXCL16 exerted potent antitumor effects by recruiting CD4 + T cells. Mechanistically, B2M loss regulated CXCL16 via suppression of Akt in MC38 and AKR cells, but via activation of NF-κB in Hepa1-6 cells.

Conclusion

CXCL16-driven CD4 + T cells are central regulators of antitumor immunity against MHC-I-deficient tumors. The context-dependent regulation of CXCL16 by MHC-I loss determines the immune landscape and tumor outcome, highlighting a potential therapeutic avenue for targeting MHC-I-deficient cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCD4-Positive T-LymphocytesHistocompatibility Antigens Class IChemokine CXCL16Carcinoma, HepatocellularImmunologic SurveillanceAnimalsMiceHumansTumor MicroenvironmentCell Line, TumorMice, KnockoutMice, Inbred C57BL

Stichwörter der Autor:innen

Escape/evasionMajor histocompatibility complex - MHCSolid tumorT cellTumor microenvironment - TME

Substanzen

Histocompatibility Antigens Class IChemokine CXCL16Cxcl16 protein, mouse

Autor:innen und Institutionen

  • Shanghai Key Laboratory for Cancer System Regulation and Clinical Translation, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China.
  • School of Biomedical Engineering, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China.
  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China.
  • Shanghai Key Laboratory for Cancer System Regulation and Clinical Translation, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China bin.ma@outlook.com.
  • Chongqing Research Institute, Shanghai Jiao Tong University, Chongqing, China.

Förderung

  • Science and Technology Commission of Shanghai Municipality
  • National 111 Project of China
  • Natural Science Foundation of Chongqing Municipality
  • National Natural Science Foundation of China
  • Peak Disciplines (Type IV) of Institutions of Higher Learning in Shanghai
  • Ministry of Science and Technology of the People’s Republic of China
  • Shanghai Jiading District Health Commission

Zitieren

APA

Zhou, Y., Chen, P., Wang, Z., Gui, L., Zheng, Z., Gao, W. Q., & Ma, B. (2026). CXCL16-driven CD4 + T cells orchestrate immunosurveillance against MHC-I-deficient hepatocellular tumors. Journal for ImmunoTherapy of Cancer, 14(5), e012347. https://doi.org/10.1136/jitc-2025-012347

Vancouver

Zhou Y, Chen P, Wang Z, Gui L, Zheng Z, Gao WQ, et al. CXCL16-driven CD4 + T cells orchestrate immunosurveillance against MHC-I-deficient hepatocellular tumors. Journal for ImmunoTherapy of Cancer. 2026;14(5):e012347. doi:10.1136/jitc-2025-012347

BibTeX
@article{Zhou2026,
  author = {Zhou, Yunyi and Chen, Ping and Wang, Zhixue and Gui, Liming and Zheng, Zhengheng and Gao, Wei-Qiang and Ma, Bin},
  title = {CXCL16-driven CD4 + T cells orchestrate immunosurveillance against MHC-I-deficient hepatocellular tumors},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {5},
  pages = {e012347},
  doi = {10.1136/jitc-2025-012347}
}
Kostenlos starten →